Name
Cytokinetics
Company Description
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patient. Please visit booth 5003 for the opportunity to discover and explore heart failure and why the sarcomere is important.
Website
Product Categories
Therapeutic Medications
ACC.25 Learning Pathways? (select all that apply)
Heart Failure and Cardiomyopathies
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth!
No
Address
350 Oyster Point Blvd
South San Francisco, 94080
South San Francisco, 94080